Anti-tumor efficacy of a potent and selective non-covalent KRASG12D inhibitor
Jill Hallin(Mirati Therapeutics (United States)), Vickie Bowcut(Mirati Therapeutics (United States)), Andrew Calinisan(Mirati Therapeutics (United States)), David M. Briere(Mirati Therapeutics (United States)), Lauren Hargis(Mirati Therapeutics (United States)), Lars D. Engstrom(Mirati Therapeutics (United States)), Jade Laguer(Mirati Therapeutics (United States)), James Medwid(Mirati Therapeutics (United States)), Darin Vanderpool(Mirati Therapeutics (United States)), Ella T. Lifset(Mirati Therapeutics (United States)), David Huy Trinh(Mirati Therapeutics (United States)), Natalie Hoffman(Mirati Therapeutics (United States)), Xiaolun Wang(Mirati Therapeutics (United States)), J. David Lawson(Mirati Therapeutics (United States)), Robin J. Gunn(Mirati Therapeutics (United States)), Christopher R. Smith(Mirati Therapeutics (United States)), Nicole C. Thomas(Mirati Therapeutics (United States)), Matthew Martinson(Pfizer (United States)), Alex Bergstrom(Pfizer (United States)), Francis Sullivan(Pfizer (United States)), Karyn Bouhana(Pfizer (United States)), Shannon L. Winski(Pfizer (United States)), Leo He, Julio Fernandez-Banet, Adam Pavlı́c̀ek, Jacob R. Haling(Mirati Therapeutics (United States)), Lisa Rahbæk(Mirati Therapeutics (United States)), Matthew A. Marx(Mirati Therapeutics (United States)), Peter Olson(Mirati Therapeutics (United States)), James G. Christensen(Mirati Therapeutics (United States))
Cited by 499
Abstract
Related Papers
No related papers found
Powered by citation graph analysis